Alzheimer’s Disease and Molecular Chaperones: Current Knowledge and the Future of Chaperonotherapy

Antonella Marino Gammazza1,2, Celeste Caruso Bavisotto1,2, Rosario Barone1,2, Everly Conway de Macario3 and Alberto J.L. Macario2,*

1Department of Biomedicine and Clinical Neurosciences, Human Anatomy Section, University of Palermo, Palermo, Italy; 2Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy; 3Department of Microbiology and Immunology, School of Medicine, University of Maryland at Baltimore; and IMET, Columbus Center, Baltimore, Maryland 21202, USA

Abstract: Background: Alzheimer’s disease (AD) is a dementia, a neurodegenerative condition, and a protein-misfolding disease or proteinopathy, characterized by protein deposits, extracellular plaques and intracellular neurofibrillary tangles, which contain the AD’s typical pathological proteins, abnormal β-amyloid and hyperphosphorylated tau, respectively, and are located predominantly in the cortex of the frontal, parietal, and temporal brain lobes. What is the role of molecular chaperones in AD? Data indicate that molecular chaperones, also known as Hsp, are involved in AD, probably displaying protective roles and/or acting as pathogenic factors as it occurs in chaperonopathies in which case AD would be suitable to chaperonotherapy. Hsp60, Hsp70, and Hsp90 can be augmented and overexpressed or diminished and downregulated in various situations in AD affected tissues and cells, indicating they are active during disease development and progression. Conclusion and Perspectives: Notwithstanding that the roles and mechanisms of action of chaperones in AD are still incompletely understood, there is already enough evidence to encourage the development of therapeutic strategies targeting them, either to block their activity in case they promote disease progression or to boost their performance when they are protective. The latter is an example of positive chaperonotherapy, which also includes chaperone replacement via gene or protein administration. On the contrary, if a chaperone is found to help the disease, it has to be blocked or eliminated, which constitute modalities of negative chaperonotherapy.

Keywords: Chaperonopathies, protein-misfolding diseases, Alzheimer’s disease, β-amyloid, tau, molecular chaperones, chaperonotherapy.

1. INTRODUCTION

Alzheimer’s disease (AD) is a form of dementia. The loss of mental power that includes, depending on clinical stage, loss of memory; diminished capacity to understand complex concepts and face daily problems and solve them rapidly; impaired ability for communication; poor judgment; disorientation; confusion; behavioral changes and other psychological and motor abnormalities; is called dementia [1-3]. The causes of dementia are varied, for example, stroke with ischemic encephalopathy (multi-infarct or vascular dementia); head trauma; hydrocephalus; encephalitis; lysosome storage disease; chronic alcoholism; demyelinating conditions such as multiple sclerosis; and neurodegenerative diseases such as AD, Parkinson’s and Huntington’s diseases, Lewy body dementia, and others.

AD is a neurodegenerative condition. Classification of neurodegenerative diseases is still a project in progress and currently includes data from epidemiology, molecular biology, molecular genetics, and genetics [4-6]. However, the classification based on the predominant anatomic location of the distinctive pathological proteins and lesions continues to be useful even today in practice, in clinics and clinical pathology. Consequently, one may speak of degenerative diseases affecting predominantly the gray matter, or the basal ganglia and nigrostriatal system, or the motor neurons, or the spinocerebellar system, among others [5, 7]. AD falls within the gray matter group, since the most affected structures are the cortex of the frontal, temporal, and parietal lobes; there is also some participation of the hippocampus.

AD is nowadays considered a member of the protein misfolding diseases [8-10]. These pathologic conditions have protein deposits, i.e., protein aggregates-precipitates, as one of the distinctive characteristics, and are considered proteinopathies. A protein is altered due to mutation or aberrant post-translational modification, namely it is a pathological form of a normal protein, and tends to form reversible aggregates and irreversible precipitates. These pathological molecules and the multimolecular deposits they form may be toxic to the cell, or may at least constitute a burden to the cell and interfere with its normal physiology. These conditions may be considered primary proteinopathies and AD is one of them.

Secondary proteinopathies are due to failure of the chaperonering system, which leads to multimolecular deposits (reversible aggregates and irreversible precipitates) of normal proteins and, even more so, of pathological proteins with tendency to aggregate. Whether this is the case for AD it is still unclear. Some data seem to
This page discusses the role of chaperones in Alzheimer's Disease (AD) and the potential for chaperone therapy. The text highlights the presence of chaperones in affected brain tissue and the idea that AD may be a chaperonopathy. Data in Table 1, which compares histopathological findings in AD specimens with another disease, show examples of pathological findings. The molecular composition of plaques and tangles is also discussed, indicating that deficiencies in the chaperoning system contribute to the development of AD.

Table 1. Examples of histopathological findings in AD specimens in comparison with findings pertaining to another gray matter disease

<table>
<thead>
<tr>
<th>Disease</th>
<th>Histopathology</th>
<th>Proteins(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer's (AD)</td>
<td>Diffuse plaques; neuritic plaques; neurofibrillary tangles; amyloid angiopathy; Hirano bodies (with actin); vacuoles with argyrophilic granule</td>
<td>APP; Aβ; tau; presenilin 1; presenilin 2; apolipoprotein E; a2-macroglobulin; caveolin; complement regulators; ubiquitin; Hsp</td>
</tr>
<tr>
<td>Pick’s (PD)</td>
<td>Pick cells with Pick bodies</td>
<td>Aβ; tau</td>
</tr>
</tbody>
</table>

*aSource: Ref. [7]. See also ref. [13].
*bProteins (and genes) normal or abnormal, known or suspected to play a role in pathogenesis. Abbreviations are: APP, amyloid precursor protein; Aβ, amyloid beta.*

The text further elaborates on the role of chaperones in AD, discussing the need for further investigation into their quantitative variations and their pathogenic or protective roles. It also touches on the development of chaperonotherapy for AD, with a focus on proteinopathies and disease mechanisms. The text concludes with a discussion on the potential for chaperone therapy and the importance of clarifying the role of specific chaperones in AD.
in overall cognitive functions, impairing the patients’ ability to carry out activities of daily living with death occurring usually within 10 years after diagnosis [3]. In 2005, AD International convened a multi-national panel of dementia experts to work on an evidence-based consensus on dementia prevalence worldwide. The panel estimated that there were 24.3 million people with dementia in the world in 2001, and predicted that this would rise to 42.3 million in 2020, and to 81.1 million by 2040 [32].

From a pathological point of view, AD is characterized by the cortical presence of extracellular deposits of amyloid-β (Aβ, Abeta), called senile or neuritic plaques, and intraneuronal inclusions, called neurofibrillary tangles (NFTs) formed by accumulation of abnormal filaments of tau, both found predominately in the brain regions involved in memory and learning [13, 18-23].

There are currently several research efforts aimed at delaying the onset of AD and the potential cytoprotective effects of the heat shock response are an attractive target for pharmacological therapies [27]. This is particularly relevant for neurodegenerative diseases associated with protein misfolding and subsequent aggregation such as AD [13, 33, 34]. Molecular chaperones, many of which are Hsp as mentioned earlier, are the main components of the chaperoning system and play a variety of roles in addition to maintaining protein homeostasis. Hsps can be overexpressed as a means for protection against stresses such as heat, oxidative stress, and ischemia. Hsp-chaperones mediate the refolding or degradation of stress-damaged proteins, depending on whether the damage is reversible or not and, thus, protect the cells from potential deleterious effects of unfolded-damaged proteins and promote the cell’s resistance to, and recovery from, stress, all events pertinent to AD [33]. Besides, Hsps have many other functions inside and outside cells; for instance, they play roles in cell division, apoptosis inhibition, and metastasis of cancer cells [14].

As mentioned earlier, many neurodegenerative diseases, including AD, are characterized by the accumulation of abnormally folded protein species [8-10], but it is not yet clear whether failure of the chaperoning system contributes to the pathogenic mechanism of AD. In other words, thus far there is no conclusive evidence that AD is a primary chaperonopathy although various observations indicate that this is a real possibility for at least some specific cases.

Chaperonopathies have been classified considering quantitative and qualitative features into by defect, by excess, and by mistake [35]. This classification is useful to establish a diagnosis with physiopathological implications and, thus, aids in decisions on treatment. Further, the classification is instrumental to conduct a differential diagnosis exercise that will lead to an accurate identification of syndrome and disease, which is key to proper patient management.

Another way of classifying chaperonopathies that also helps the physician and, therefore, the patient, is based on whether they are inherited (genetic) or acquired [14]. The pathogenic chaperone may be normal or structurally altered and belong to any of the known Hsp-chaperones groups (Table 2). The structural alteration of a pathological chaperone may affect any of its functional domains or modules. When the chaperone is deficient, the aim is to replace it or to boost its functionality, and we can refer to this therapeutic modality as positive chaperonotherapy. If, on the contrary, the chaperone favors disease rather than protecting the cell and the organism, the therapeutic strategy aims at eliminating or blocking the pathological chaperone. This latter therapeutic modality may be referred to as negative chaperonotherapy [25, 27].

Involvement of chaperones in the pathogenesis of AD was first proposed following promoter analysis of the amyloid precursor protein (APP) gene, where a heat shock element (HSE) was found within its promoter [36]. As mentioned earlier, molecular chaperones play essential roles in many cellular processes including pro-

### Table 2. Subpopulations of Hsp-chaperones by molecular weight found to cause chaperonopathies

<table>
<thead>
<tr>
<th>kDa</th>
<th>Classical family</th>
<th>Others causing chaperonopathies</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥200</td>
<td>None</td>
<td>Sncsin</td>
</tr>
<tr>
<td>100 - 199</td>
<td>Hsp100 - 110</td>
<td>VCP</td>
</tr>
<tr>
<td>81 - 99</td>
<td>Hsp90</td>
<td>Paraplegin [SPG7]; UNC45B</td>
</tr>
<tr>
<td>65 - 80</td>
<td>Hsp70/DnaK</td>
<td>Spastin [SPG4]</td>
</tr>
<tr>
<td>55 - 64</td>
<td>Hsp60 (chaperones Groups I and II, e.g., Cpn60 and CCT-BBS)</td>
<td>BAG3; immunophilins FKB-type: peptidyl-prolyl cis-trans isomerases (PPI; FKBP5; FKBP10); myocilin; protein disulfide-isomerases (PDI; ER); SERPINH1 (Hsp47)</td>
</tr>
<tr>
<td>35 - 54</td>
<td>Hsp40/DnaJ</td>
<td>AIP, AIPL1; BCS1L; CALR; clusterin; DNAJC19; FOXRED1; melusin; morgana; SIL1; TBCE; torsin A</td>
</tr>
<tr>
<td>&lt;34</td>
<td>sHsp (crystallins)</td>
<td>Alpha Hemoglobin-Stabilizing Protein (AHSP); alpha-synuclein; BCAP31; frataxin; Hsp10 (Cpn10); HSPB11; immunophilin cyclophilin-type: peptidyl-prolyl cis-trans isomerase (PPI; PPIB); LRPAP1; RP2; SOD1-2</td>
</tr>
</tbody>
</table>

*aSource: Ref. [14].
tein folding, translocation across membranes, refolding, and degradation, and also in disaggregation of protein aggregates (see references earlier). This explains why molecular chaperones are essential in the cellular defense against protein aggregation caused by misfolding both at intra- and extra-cellular levels and are potentially powerful suppressors of neurodegeneration. Moreover, chaperones regulate protein functions in order to protect against the oxidative stress accompanying the toxicity of amyloid aggregates and their expression is increased under conditions of amyloid challenge [37]. Also, a “sink hypothesis” has been proposed, postulating that cellular toxicity and other manifestations of chaperone deficiency in AD, and other similar conditions, may develop because chaperones are being sequestered on the amyloid fibrils, as well as on the other protein precipitates and, thus, are redirected away from their normal cellular tasks [38]. This situation can be described as a chaperonopathy by default due to a quantitative deficit of chaperones at the time and place, i.e., where and when, they are needed [14]. Here, we discuss growing evidence suggesting a convergence between AD and molecular chaperones and the possibility that this disease may be a chaperonopathy. This approach provides a convenient point of view to examine AD and to look for new therapeutic avenues. In this chapter, we focus on Hsp60, Hsp70, and Hsp90, discussing some of their biological, molecular, and pathological facets as they pertain to AD.

2.1. Hsp60

Hsp60 is classically described as a mitochondrial protein whose gene is induced by various types of stressors as heat shock, oxidative stress, and DNA damage [39]. Inside mitochondria, Hsp60 acts as a folding machine, together with Hsp10, for the correct folding of several mitochondrial proteins [40, 41]. Various studies, published over the past several years, have demonstrated new subcellular locations and functions for Hsp60, describing it as a ubiquitous molecule with multiple roles in health and disease [42-44]. Moreover, detailed studies of the structure of Hsp60 have been reported that help understand the functions of this multifaceted molecule [45, 46].

Hsp60 has both pro-survival and pro-death functions depending on tissue, cell type, and apoptosis inducers [47, 48]. It has been demonstrated that Hsp60 may associate with Bak or Bcl-XL in normal heart tissue, inhibiting their apoptotic potentials and consequent cytochrome c release [49]. Hsp60 may influence tumor progression as suggested by its accumulation in the cytosol and plasma membrane of cancerous cells, reaching the extracellular space via secretory vesicles that in turn can modulate (induce, or inhibit?) anti-tumor immune responses [50-52]. Hyperacetylation of Hsp60 in osteosarcoma cells is associated with the anticancer activity of geldanamycin and Hsp60 nitration is associated with the anti-tumor action of the histone deacetylase inhibitor SAHA [53, 54]. These findings support the idea that Hsp60 is a suitable target for anti-tumor therapy and opens new prospects for novel drugs design [55], a concept that can be extended to the developing of agents to treat AD.

On the other hand, there exists published evidence supporting a cell death-promoting function for Hsp60. Mitochondrial Hsp60 binds pro-caspase 3 in Jurkat and Hela cells, accelerating the maturation of pro-caspase 3 by upstream activator caspases during apoptosis [56, 57].

Hsp60 has also been implicated in the mechanism of cell aging [58]. Senescent cells in culture become flat and enlarged and can be maintained in a viable state for long periods, but cannot be induced to divide by mitogenic stimuli [59]. Senescence-induced resistance to apoptosis leads to an increase in the number of senescent cells inside tissues, with consequences on the feebleness of tissue integrity and on neoplastic transformation, likely promoting the development of late-life cancers [60]. During replicative senescence of normal human skin fibroblasts, the levels of Hsp60 increase and form a complex with MOK, a MAP kinase involved in signal transduction to the nucleus [61]. Furthermore, a correlation between increased levels of Hsp60 and senescence of skin fibroblasts was shown to involve interaction between Hsp60 and mHsp70 [62].

Hsp60 may be involved in autoimmune processes: it may act as autoantigen because of the high sequence similarity (molecular mimicry) between human and foreign Hsp60 from bacteria and parasites that colonize humans, which leads to anti-Hsp60 antibody cross-reactivity [14, 63]. Hsp60 has high structural similarity also with human proteins such as myelin-associated protein, glutamic acid decarboxylase, and acetylcholine receptor, further suggesting that circulating Hsp60 may serve as autoantigen for the generation of an autoimmune response [14]. Consequently, Hsp60 may trigger autoimmune pathological conditions, including some affecting the nervous system such as multiple sclerosis and myasthenia gravis [14, 64].

Extracellular Hsp60 can interact with a variety of receptors present on the plasma-cell membrane surface, such as CD14, CD40, CD91, and TLRs [65, 66]. Hsp60 influences the pro-inflammatory capacity of adipocytes binding an adipocyte receptor and contributing to obesity-associated inflammatory disease leading to diabetes [67]. The chaperonin has also been implicated in the pathogenesis of chronic inflammatory conditions such as Crohn’s disease [68], ulcerative colitis [69, 70], alcoholic liver disease [71], chronic obstructive pulmonary disease [72], and atherosclerosis [73].

Neural expression of Hsp60 increases over the course of development, a trend consistent with the changes of mitochondrial content in the brain [74]. In brain, Hsp60 is endogenously expressed in astrocytes, neurons, microglia, oligodendrocytes, and ependymal cells [74]. This distribution suggests an active participation of this chaperonin in many functions of the brain, both in normal and pathological conditions. Hsp60 exposed on the surface of astrocytes and neuroblastoma cells interacts with TREM2, a receptor that, if mutated, is responsible for genetic disorders affecting bones and brain [75]. Extracellular Hsp60, through binding to LOX-1 (lectin-like oxidized low-density lipoprotein receptor-1), may promote microglia-mediated neuroinflammation and a prolonged delay in the induction of Hsp60 in injured regions of the brain [76, 77]. For example, expression of Hsp60 has been found increased in the brainstem after subarachnoidal haemorrhage, forebrain or focal cerebral ischemia, and neonatal hypoxia-ischemia [77]. Increased levels of the chaperonin have also been found in both animals and patients with temporal lobe epilepsy in response to epileptic seizures [78].

Given that Hsp60 plays a critical role in assisting the correct folding of other mitochondrial proteins and enzymes, a deficiency in its concentration and/or function together with the increased vulnerability to oxidative stress observed in the tissues of neurodegenerative disorders, may lead to severe conditions caused by protein misfolding and aggregation [24, 79]. This would be an Hsp60 chaperonopathy.

Post-translational modifications (phosphorylation, acetylation, Y-nitration, S-nitrosylation, methylation, oxidation, and ubiquitination) of Hsp60 may occur through a variety of mechanisms, resulting in the loss or impairment of its functions [54, 80]. Such Hsp60 deficiency might be a common cause of mitochondrial dysfunction, which would be significant since AD has been described as a disorder aggravated by oxidative stress and/or mitochondrial defect characterized by protein conformation abnormalities (Fig. 1) [29, 30, 77, 81].

Hsp60 was found to be involved in preventing aggregation by trapping misfolded forms of prion protein scrapie ant thus preventing glycation, which is known to contribute to the pathogenesis of protein deposition [82]. Expression of Hsp60 is significantly decreased in the parietal cortex of AD subjects and in the cerebellum of Alzheimer's Disease and Molecular Chaperones

Stress and Hsp60 in Alzheimer’s disease: possible pathogenic pathways. Oxidative stress (and other types of stress) may cause Hsp60 alterations, e.g., post-translational modifications, resulting in an impairment or loss of the chaperonin’s functions with various consequences (some of which are indicated in the figure) and, thus, contributing to the development and/or progression of Alzheimer’s disease. UPR, unfolded protein response.

A rat model of AD, suggesting a defect in the protective role of this chaperonin in the AD brain [81, 83]. In support of the neuroprotective effects of Hsp60, it has been demonstrated that in a human neuroblastoma cell line, induced expression of the chaperonin prevented intracellular β-amyloid-induced inhibition of complex IV and consequently reduced apoptosis [84]. Aβ25–35 induced oxidation of Hsp60 in fibroblasts derived from AD patients [85] and, also, Hsp60 was oxidized by Aβ1-42 leading to a loss of function of the chaperonin, which caused an increase in protein misfolding and aggregation [86]. Again, this would be a chaperonopathy by defect.

Hsp60 levels were found elevated in lymphocytes from AD patients when compared to controls [87] and sporadic AD subjects exhibited a significant (~40-60%) increase in expression levels of genes activated by the mitochondrial unfolded protein response (mtUPR), including genes encoding mitochondrial chaperonins such as Hsp60 and others [30].

Administration of an Aβ amyloid-Hsp60 peptide-conjugate vaccine led to the induction of anti-Aβ-specific antibodies, associated with a significant reduction of cerebral amyloid burden and of the accompanying inflammatory response in the brain of a mouse model of AD [88]. On the contrary, other authors have attributed a deleterious effect to the elevated expression of Hsp60 in AD. For example, it was shown that Hsp60 mediates in vitro the translocation of APP to the mitochondria leading to dysfunction of this organelle [89].

All the findings discussed in the preceding paragraphs indicate that more research is needed to determine with certainty if AD is an Hsp60 chaperonopathy by defect, or by excess, or by mistake. However, the data do show that this chaperonin is implicated in the disease and deserves more research to clarify what it does, when, and how, as a fundamental preliminary step to the developing of specific Hsp60 chaperonotherapy, positive or negative, as the case might be.

2.2. Hsp70

The Hsp70 family is large with at least 17 members [90], some of which are stress-inducible (e.g., HSPA1A also named Hsp70a), while others are constitutively expressed (e.g., HSPA8 also called Hsc70). The stress-inducible Hsp70 proteins are among the first to be upregulated upon heat shock to cope with the protein damage-misfolding caused by stress. Hsp70 chaperones are found in most cellular compartments, including the nucleus and cytoplasm (Hsc70), mitochondria (mtHsp70, also named HSPA9 and mortalin), and ER (Grp78, also known as BiP) [90, 91].

Hsc70 assists the folding of client proteins via an ATP-dependent mechanism binding to short extended hydrophobic regions of the misfolded client proteins and, thereby, prevents aggregation of the unfolded clients [92]. By differentially associating with the co-chaperones Hsp40, and with Hsp90, Hsp70 achieves versatility of function in the various cellular compartments [93].

Hsp70 inhibits apoptosis acting on the caspase-dependent pathway at several steps both upstream and downstream of caspase activation and, also, on the caspase-independent pathway. A study of the correlation between the anti-apoptotic effects of Hsp70 and inhibition of caspase activity suggested that the point of Hsp70 intervention was upstream of caspase-3 activation. Subsequently, it was demonstrated that Hsp70 is able to directly inhibit caspase processing by interacting with Apaf-1 and prevent the recruitment of procaspase-9 to the apoptosome [94]. Overproduction of Hsp70 leads to increased resistance against apoptosis-inducing agents such as tumor necrosis factor-a (TNFa), staurosporin, and doxorubicin, while downregulation of Hsp70 levels by siRNA leads to increased sensitivity towards these agents [95-97]. In various kinds of tumors increased Hsp70 levels are observed that correlate with increased malignancy and resistance to therapy [98]. For example, Hsp70 binds tumor-suppressor proteins, such as p53 and HER2, and thus allows unlimited cellular growth and increased resistance to chemotherapy in breast cancer, consequently, elevated levels of Hsp70 are associated with poor prognosis in breast and endometrial cancers [98]. Downregulation of the Hsp70 levels in some types of cancers induce differentiation and cell death [99].

Hsp70 has the ability to trigger the activation of the immune response by stimulating both innate and adaptive immunities. The immunogenicity of Hsp70 and its capacity to activate antigen-specific immunity have made this protein a promising candidate for vaccine development. With respect to innate immunity, Hsp70 is secreted from host cells into the extracellular milieu, and this extracellular Hsp70 triggers innate immunity via activation of antigen presenting cells (APCs) [100]. Regarding adaptive immunity, Hsp70 is an abundant antigen for both B and T cells. For example, the P. falciparum Hsp70 is expressed by most parasites during their life cycles and it is recognized by serum antibodies from malaria patients [101].

The numerous roles of the various Hsp70 proteins relate not only to onco genesis and the immune response, as discussed above, but also to other pathological processes, such as neurodegeneration and senescence. Neurodegenerative diseases such as AD, Parkinson’s disease, Huntington’s chorea, and spinocerebellar ataxias are characterized by excessive apoptosis. In some model systems, overexpression of Hsp70, or one of its co-chaperones, was shown to overcome the neurodegenerative symptoms induced by expression of a disease-related gene [102, 103].

Senescence in cell culture as well as aging in vivo is correlated with a continuous decline in the ability to mount a stress response [104]. Age-related symptoms and diseases reflect this decreased ability to cope with cellular stresses. Interestingly, centenarians seem to be an exception to the rule, as they show a significant induction of Hsp70 production after heat shock challenge [105]. In the brains of patients affected by AD, an increased level in the expression of Hsp70 has been reported [106], suggesting a potential role of Hsp70 in the pathogenesis of this disease. APP interacts with the ER resident chaperone BiP/Grp78 during its normal processing in the ER-Golgi pathway, suggesting that an increase of
Grp78 levels may help proper processing of APP therefore reduce amyloid production [107].

Immunohistochemical studies and expression analyses in AD brain tissue showed that expression levels of Hsp70 were elevated in affected regions, and this elevation appeared to be correlated to the presence of activated glia and dysregulated or stressed neurons [33]. The increase in Hsp70 levels could be related to an increase in the expression of the transforming growth factor β1 (TGF-1), an enzyme that is thought to be responsible for the degradation of Aβ [108]. In addition, cytosolic Hsp70 was shown to inhibit early stages of amyloid aggregation protecting against intracellular Aβ [109]. It was reported that chaperone proteins, including Hsp70, can recognize abnormal tau and reduce its concentration by facilitating its degradation and de-phosphorylation [110-112]. Moreover, it has been demonstrated that tau binds directly to Hsp70, and Bag-1 has a role in this interaction [113]. Therapeutics that exploit the ability of Hsp70 to selectively target abnormal tau can rapidly and potently rescue the synaptic dysfunction that occurs in AD and other tauopathies [114].

It is clear from the above paragraphs that various members of the Hsp70 family are implicated in AD and it is also apparent that, as the pathogenic and/or protective mechanisms in which these chaperones (with or without their co-chaperones) participate are being elucidated, new perspectives for Hsp70 chaperonotherapy will be unveiled.

### 2.3. Hsp90

Hsp90, of which in humans there are at least five varieties (HSP90A in cytosol; HSP90alpha, HSP90beta, HSP90B (or Grp94) in the ER, and TRAP in mitochondria [14]) is the most abundant protein in eukaryotic cells under unstressed conditions, and like other molecular chaperones, is present in one form or another in most cellular compartments such as the cytosol, endoplasmic reticulum, mitochondria, and chloroplast [115]. Hsp90 is indispensable for cell survival, playing an important role in the folding of many proteins pertaining to essential signalling pathways, and in the refolding of denatured proteins after stress [115, 116]. Hsp90 is an ATP-dependent chaperone, with a unique N-terminal ATP binding site (in addition to another C-terminal nucleotide binding site) that has allowed for the development of specific Hsp90 inhibitors such as geldanamycin, a macrocyclic antitumor agent and its less toxic analog 17-allylamino-17-demethoxygeldanamycin (17AAG) [115]. Hsp90 does not bind to non-native proteins but rather to substrates in their native states and targets a specific set of client proteins that are involved in signal transduction [117].

Hsp90 has been shown to interact with important client kinases, including ErbB2, Src, Abl, and Met tyrosine kinases, and cyclin-dependent serine kinases [116], which are part of an intricate multidimensional signalling web that integrates information from various origins. Many of these client proteins are known to be bound to Hsp90 in an inactive state and are activated upon dissociation from Hsp90. For example, the catalytic domain ofraf proteins, members of MAP kinase kinase kinases (MEKKs), are in a heterocomplex with Hsp90, and are activated upon dissociation from this Hsp90 such as in stress conditions [107]. Moreover, the abundant cytosolic Hsp90 under normal conditions has the capacity to bind to and keep stress transcription factors such as Heat Shock Factor-1 (HSF-1) in a monomeric inert state. Upon heat shock, HSF-1 is released from the Hsp90 complex due to the increased demand for chaperone proteins in need of assistance for folding and refolding. This represents the first step in the activation of HSF-1 and the inducible Hsp90 offers a negative feedback loop to control the transcriptional activity of HSF-1 [107].

Hsp90 is overexpressed in cancer cells and is essential for the malignant transformation and progression of several tumor types such as bladder, breast and lung cancers, and leukemia [98, 118]; these being examples of chaperonopathies by mistake. Consequently, blockage of Hsp90 function in these cancers via inhibitory compounds may be a valuable therapeutic strategy [119], and by extension the same principles may be applied to the developing of compounds to treat AD if it is demonstrated that Hsp90 favors disease (AD would thus be an Hsp90 chaperonopathy by mistake).

Some observations suggest an additional role for Hsp90 in buffering some of the client proteins that might be directly responsible for disease progression [120, 121]. Hsp90 was shown to inhibit early stages of amyloid aggregation [109] and administration of Hsp90 inhibitors to primary neurons prevented Aβ-induced neurotoxicity [122]. The complex of Hsp90 and Hsp70/Hsp40 also can inhibit Aβ formation and slow down the rate of aggregation in a chaperone concentration-dependent manner (Fig. 2) [123]. Hsp90 outside the cells may facilitate Aβ clearance by the activation of microglial phagocytosis and Aβ degradation by NF-κB and p38 MAPK activation through the Toll-like receptor-4 (TLR4) pathway [109, 124]. All these observations suggest that positive chaperonotherapy centred on Hsp90 could be a promising means to treat AD.

The other hallmark of the pathology of AD is the accumulation of tau, which leads to the formation of toxic NFTs. Chaperones are necessary to maintain tau in a non-aggregated state. Positive correlations have been found in the soluble protein levels from AD brain tissue between tau and molecular chaperones including Hsp90 [125]. Hsp70 and Hsp90 work together to coordinate tau homeostasis [126]. Pharmacologic inhibition of Hsp90 significantly reduced intracellular levels of the disease-associated phosphorylated tau species PS202/T205 and PS396/S404 (Fig. 2) [33]. These Hsp90 inhibitors primarily facilitate the clearance of phosphorylated tau via proteasomal degradation [33]. Mutant tau is maintained in tauopathies by Hsp90 and the inhibition of Hsp90 leads to reduction in the pathogenicity of these mutant species [121]. These data suggest that negative chaperonotherapy aimed at Hsp90 inhibition might offer hopes for developing efficacious treatment for AD.

Important regulators of the Hsp90 machinery are co-chaperones and posttranslational modifications, e.g., acetylation, nitrosylation, and phosphorylation, of the Hsp90 protein itself [115]. For instance, the acetylation of Hsp90 inhibits client binding thereby enhancing the proteasomal degradation of the unbound clients. Tau is a client for Hsp90 complexes. If tau is in an abnormal or modified form, then it can trigger the recruitment of CHIP, a cochaperone of Hsp90, to the complex, which induces the ubiquitination of tau and activates its downstream degradation steps [123].

Hsp90 inhibition may be suitable to a dual therapeutic approach in AD (Fig. 2). On the one hand, Hsp90 inhibitors may counteract tau protein hyper-phosphorylation and subsequent aggregation. On the other hand, Hsp90 inhibitors may reduce the protective stress response. Hsp90 can tightly bind and thus down-regulate the activity of HSF-1 but in the presence of cellular stress (a common event in AD), HSF-1 dissociates from Hsp90, translocates to the nucleus and binds heat-shock response elements, thereby inducing heat shock response genes, such as those encoding the proteins Hsp27, Hsp40, Hsp70, and Hsp90. The expression of these chaperone genes expands the buffering capacity of the cell and restores protein homeostasis under stressful conditions [127].

Another aspect to take into account in this context is that cell life and functions depend on many extracellular signals and that these signals, in turn, depend on carriers that travel communicating different cells. In the last years, growing evidence supports the pivotal role of the extracellular vesicles (EVs), such as exosomes, in cell-cell communication. The roles of exosomes in mediating the pathogenesis of AD were initially attributed to the capacity of these nanovesicles to serve as vehicles for the transport of the Aβ peptides to the extracellular environment [128]. Recently, it has been demonstrated that Hsp70 and 90 intercellular transport via exosomes contributes to maintenance of protein homeostasis at the organismal level [129]. The data indicate that EVs are promising
elements for directing specific therapeutic agents to selected cells in which the chaperoning system needs re-enforcements or repair.

Since neurons are a terminally differentiated, i.e., they are a post-mitotic cell type, it has been suggested that neurons are especially susceptible to the cumulative effects of misfolded proteins as they are unable to reduce the load of toxic intermediates through consecutive rounds of mitosis [37]. Therefore, the capacity of neuronal chaperones to reduce misfolded proteins is essential for maintaining neuronal integrity. This again clearly points to positive chaperonotherapy as one promising treatment modality for AD.

CONCLUSION AND PERSPECTIVES

From the data discussed in the preceding three sections, we can say for Hsp60, Hsp70, and Hsp90 that there are clear indications of their active participation in the cellular and tissue phenomena typical of AD, but the pertinent molecular mechanisms are still not fully understood. Nevertheless, there is growing evidence suggesting that the development of pathological features in AD could be the result of chaperone malfunctioning by excess, defect, or mistake. Consequently, AD is a candidate for chaperonotherapy in its various forms, positive, negative, and combined. These possibilities are currently under intense scrutiny in our laboratories and in those of many others, ensuring a bright future for research on this serious and widespread neurodegenerative condition and nurturing hope for those affected by it.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

This work was supported by the Euro Mediterranean Institute of Science and Technology, and funded with the Italian National Operational Programme for Research and Competitiveness 2007-2013 grant awarded to the project titled "Cyber Brain – Polo di innovazione" (Project code: PONa3_00210, European Regional Development Fund). A.J.L.M. and E.C. de M. were partially supported by IMET; A.J.L.M. and F.C. were partially supported by IEMEST. This work was done under the umbrella of the agreement between the Euro-Mediterranean Institute of Science and Technology (Italy) and the Institute of Marine and Environmental Technology (USA) signed March 2012 (this is IMET contribution number IMET 16-175).

REFERENCES

Alzheimer's Disease and Molecular Chaperones


Kovacs GG. Current concepts of neurodegenerative diseases. EMJ Neuro 2014; 1: 78-86.


